AKT1 and chronic obstructive pulmonary disease: Therefore, the potential mechanism by which the JPYF II Formula treats COPD might involve quercetin, kaempferol, and stigmasterol acting on TNF, downregulating the PI3K/AKT signaling pathway, and thus achieving the effect of inhibiting the inflammatory response.